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Dissertation
ABSTRACT
This study explores the marketing practices of small biotechnology companies. 
The recent critical literature has questioned the direct applicability of traditional 
marketing concepts (e.g., sales, advertising, PR, pricing, etc.) to specific types of 
businesses, such as science-based and high-tech start-ups, and within the small 
business context more generally. This study contributes to the small business mar-
keting literature by examining how marketing practice emerges and evolves in 
biotechnology start-ups. The primary data were collected during two years of eth-
nographic fieldwork examining a team of natural scientists who had established 
a university spin-off company. In addition, the dataset includes documents and 
interviews. This study introduces a new type of marketing practice called science 
marketing, which has not yet been identified in previous studies. The analysis 
reveals, first, how the practice of science marketing emerges in a biotechnology 
start-up and how science marketing differs from traditional marketing. Second, 
the analysis illustrates how an embodied and routinised means of promoting 
scientific work is transferred from a research group to the start-up to be infused 
and combined with more traditional marketing activities. As part of science mar-
keting, the scientists conducted academic activities, such as publishing journal 
articles, making conference presentations and compiling publication lists, which 
are tasks that the previous literature has regarded as stubborn preoccupations of 
science but which have become an understandable and valuable asset in market-
ing small science-based ventures such as biotechnology start-ups. 
Keywords: marketing, practice, science marketing, biotechnology
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Väitöskirja 
ABSTRAKTI
Väitöskirjassa tarkastellaan pienten bioteknologiayritysten markkinointikäy-
täntöjä. Aiempi kriittinen kirjallisuus on kyseenalaistanut perinteisten mark-
kinointikäsitteiden (esim. myynti, mainonta, PR, hinnoittelu, jne.) sopivuuden 
pienyritysympäristöön yleensä sekä erityisesti high-tech- ja tiedepohjaisiin yri-
tyksiin. Tutkimus laajentaa ymmärrystä markkinoinnista tarkastelemalla miten 
pienyrityksen markkinointikäytäntö syntyy ja kehittyy bioteknologia-alan start-
up-yrityksissä. Tutkimuksen etnografinen pääaineisto on kerätty kahden vuo-
den aikana bioteknologia-alan tutkijaryhmässä, joka perusti start-up-yrityksen. 
Etnografisen aineiston lisäksi aineistona on käytetty haastatteluja ja dokumentteja. 
Tutkimuksen avulla tunnistettiin uuden tyyppinen markkinointi, tiedemarkki-
nointi, joka ei ole tullut esiin aiemmassa kirjallisuudessa. Tutkimuksen analyysi 
näyttää miten markkinointikäytäntö muodostuu bioteknologia-alan start-up-
yrityksessä ja miten tiedemarkkinointi eroaa perinteiseen markkinointikäsittee-
seen perustuvasta markkinoinnista. Lisäksi tutkimus kertoo miten kehollinen ja 
rutinoitunut tapa tieteellisen työn edistämiseen siirtyy alkavaan yritykseen ja 
kietoutuu perinteisiin markkinointiaktiviteetteihin. Yrityksessä työskentelevät 
tutkijat jatkavat tiedemaailman aaktiviteetteja, kuten julkaisevat artikkeleita, te-
kevät konferenssiesiintymisiä ja koostavat julkaisuluetteloja. Tutkimus näyttää, 
miten nämä aktiviteetit, joita on aiemmin pidetty itsepäisenä keskittymisenä vain 
tieteen tekemiseen, ovatkin ymmärrettäviä ja arvokkaita asioita pienten biotekno-
logiayritysten markkinoinnissa. 
Asiasanat: markkinointi, käytäntö, tiedemarkkinointi, bioteknologia
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PART I
1 Introduction
It was 2 a.m. on a dark, cold and windy night. I was sitting in my car in the parking lot 
of a university waiting for my sister, who was inside the building at the chemistry lab 
checking her laboratory reactions. I was curious to see her lab, but the rule was that NO 
OUTSIDERS were EVER allowed inside the premises. So I waited outside and let my 
mind wander. I was then an entrepreneur and had been running my marketing-based 
business for several years. Sitting there in the darkness, I could not help but think how 
much scientists seemed to have in common with entrepreneurs. To me, it seemed to be in 
the entrepreneurial spirit to wake up in the middle of the night and rush in to check your 
test tubes and Erlenmeyer flasks.  
So I sat there and watched the dark, unapproachable building. Its thick, massive door 
separated me from my sister: She was inside doing magical things, and I was outside, 
sitting in the dark. I felt a strong urge to know what was inside. I was not particularly 
interested in the science per se but in the people who worked inside. If they were to have 
looked outside from the tiny windows in my direction, what would they have seen? What 
would they consider to be in the entrepreneurial spirit? How would they see business? 
What would they think about marketing? Somehow, I felt that if I could only learn to see 
“with their eyes”, I would have a completely new perspective on myself, on marketing and 
on business in general. This insight was one of the impulses that motivated my journey to 
study biotechnology marketing.
1.1 THE CONTEXT AND OBJECTIVES
Few industries face such immense expectations as biotechnology does. Although 
biotechnology as a discipline dates back to the first production of beer, bread and 
wine using living organisms (Hine & Kapeleris 2006), biotechnology as a business 
is a much more recent phenomenon. The group of companies that began using 
biotechnology are regarded as the first industry to emerge as a consequence of 
a series of scientific discoveries: the 1953 discovery of the double helix, the 1957 
discovery of the interferon, the development of recombinant DNA in 1973 and 
the production of monoclonal antibodies in 1975 (Prevezer 1997, Pisano 2006). The 
first science-based biotechnology company was founded as an alliance between 
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venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer in 1976 
to exploit recombinant DNA technology (Pisano 2006); this alliance combined two 
traditionally separate fields of expertise, basic science and business, into a new 
venture (Pisano 2006, Powell & Owen-Smith 1998). Before these first biotechnology 
companies, science and business had largely operated in separate spheres (Pisano 
2006, Lehrer & Asakawa 2004), and the biotechnology industry is generally re-
garded as the first instance of an entire industry based on discoveries in basic sci-
ence (Pisano 2006). At present, the biotechnology industry consists of companies 
of various sizes that produce or employ biotechnological applications as part of 
their business. These companies operate in fields as diverse as pharmaceuticals, 
agriculture and chemicals (Hall & Bagchi-Sen 2007).  
In this study, I focus on small business marketing and, more specifically, on 
biotechnology marketing; thus, the context of this study is a small biotechnology 
company. As a combination of science and business, the biotechnology business is 
a particularly interesting research context because it has several features that dis-
tinguish it fundamentally from other businesses. These characteristics affect mar-
keting decisions and the activities performed by marketing practitioners. In cer-
tain specific contexts, such as biotechnology businesses, approaches that assume 
that marketing concepts apply across industries and that marketing definitions 
can be generalised have major shortcomings with respect to guiding researchers 
and practitioners (Stemersch & Van Dyck 2009). In addition, there is evidence that 
companies have failed in certain unique industries because they followed general 
marketing principles in contexts that were not traditional (Christensen 1997). In 
this study, I argue that understanding the nature of marketing requires a focus on 
the everyday activities of practitioners and how marketing is conducted in prac-
tice (Brown 1999, Stemersch & Van Dyck 2009). Using practice as a lens to study 
marketing makes it possible to obtain a better understanding of the activities and 
different elements that comprise a marketing practice. Therefore, my research 
question in this study is the following.
How the biotechnology marketing practice is constituted in small biotechnology com-
panies?
Biotechnology companies operate at the challenging intersection of science and 
business, which are traditionally entirely separate areas (Pisano 2006). The em-
bedded nature of knowledge and the diversity of the social worlds of science and 
business raise significant challenges with respect to ensuring that partners from 
these different cultures understand one another (Polanyi 1967, Szulanski 1995, 
1996). Individuals from different backgrounds employ different meanings in their 
functional settings and cannot easily share ideas; thus, they may ignore one an-
other’s central ideas or reject them outright (Dougherty 1992). The literature has 
identified a significant role for individuals who are able to bridge scientific knowl-
edge and innovation (Gittelman & Kogut 2003) and can act as knowledge brokers 
or boundary spanners (Levina & Vaast 2005). Operating a biotechnology business 
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requires creating a “mutual understanding” in which individuals can overcome 
these semantic differences by making tacit knowledge explicit across boundaries 
(Nonaka 1994). Thus, the following is my first sub-question:
1. How are science and business connected in small biotechnology companies?
Marketing practice draws on the social, historical, structural and institutional 
setting in which the company under examination is embedded. Practices are situ-
ated in a context that is partly given but simultaneously (re)produced through 
the practices employed (Orlikowski 2010). Thus, the context has a dual nature: 
the practice sustains and shapes the organisational reality in which it is situated. 
Thus, to understand a marketing practice, the context (Corradi et al. 2010, Nicolini 
2013) in which such practice is conducted must also be understood. As a result of 
its historical roots in academic research and scientific discoveries, the biotechnol-
ogy industry is characterised by several features that distinguish it from other 
industries and features a structure that is fundamentally different than that found 
in more traditional industries. Thus, my second sub-question is the following:
2. What is the context for small business marketing in biotechnology?
The gap between marketing theory and practice has been a recurring theme in 
numerous contemporary debates (Ardley 2008, McKenzie et al. 2002, Brennan 
& Ankers 2004, Reed et al. 2004, Skålen & Hackley 2011). Among other topics, 
critics of marketing theory have questioned the relevance of general marketing 
theory for small businesses (Reijonen 2010, Coviello et al. 2000) and in entrepre-
neurial contexts (Hills et al. 2008, Martin 2009). Given the increasing interest in 
the biotechnology business, it is surprising how little research has focused on 
how marketing is actually undertaken in these organisations. Prior research has 
argued that marketing-related deficiencies might explain the lack of commercial 
success in biotechnology (Costa et al. 2004, Hermans et al. 2004). Alternatively, 
it has been suggested that biotechnology marketing might differ from what is 
considered marketing in other industries (Renko 2006), which results in the ques-
tion of whether there are deficiencies in biotechnology marketing or whether the 
definition of biotechnology marketing remains unexplored by the survey-based 
research designs that have been employed in prior studies. Thus, my third sub-
question is as follows:
3. How do small biotechnology companies engage in marketing?
The combination of biotechnology’s origins in basic science and the multidiscipli-
nary nature of biotechnology innovations results in a set of unique features that 
characterise biotechnology companies (Owen-Smith & Powell 2004, Etzkowitz & 
Leyesdorff 2000, Tahvanainen 2004). Biotechnology companies are typically estab-
lished by university scientists who work for these companies on a part-time ba-
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sis while maintaining their university researcher positions and academic careers 
(Zomer et al. 2010, Prevezer 2008, Hermans et al. 2004). Thus, biotechnology’s ori-
gins in basic science have combined with the multidisciplinary nature of biotech-
nology innovations (Owen-Smith & Powell 2004, Pisano 2006) that generates the 
unique context from which biotechnology marketing emerges. This unique con-
text calls for a new approach in research, one that accounts for the specific nature 
of the biotechnology business. In this study, therefore, I adopt a practice-based 
approach that focuses on what actually occurs in organisations rather than ad-
dressing the theories and representations of various researchers; thus, this study 
has the potential to broaden the concept of marketing and to provide relevant 
and valuable insights for both marketing practice and academic research (Ardley 
2008, McCole 2004, Srinivasan 2008, Stemersch & Van Dyck 2009). Thus, my fourth 
sub-question is the following:
4. How does science marketing emerge?
1.2 RESEARCH APPROACH
In this study, I employed a combination of practice-based approaches, which al-
lowed me to provide a richer description (Nicolini 2013) that is capable of ren-
dering a more detailed, accessible and understandable picture (Geertz 1973) of 
biotechnology marketing practice. In all my articles, I attempt to understand the 
reality of biotechnology marketing, although the articles draw from different 
theoretical backgrounds that I will explain below. The first two articles focus on 
the context in which small biotechnology companies perform their marketing 
practice. In the last two articles, written with Päivi Eriksson, we first focus on the 
activities of biotechnology marketing, and then, in the final article, we conceptu-
alise biotechnology marketing practice.
Biotechnology companies operate at the challenging intersection of science and 
business, which are traditionally entirely separate areas (Pisano 2006). This nexus 
of scientists and marketers is intriguing because the differences between these 
two social and cultural worlds—basic science and business—have created signifi-
cant challenges for business partners in terms of mutual understanding (Polanyi 
1967, Szulanski 1995, 1996), and this culture clash thus occasionally results in failed 
ventures (Samson & Gurdon 1993). The extent to which practitioners from these 
two communities are able to collaborate effectively depends on how they are able 
to resolve the indexicality, i.e., how they are able to (re)negotiate shared meanings 
and understandings (Gherardi 2008). These constant negotiations occur in practice 
and through practice (Gherardi 2009, Gherardi 2008); in this process, the parties 
negotiate a shared way of understanding the world and the desirable outcome of 
a given practice (Reckwitz 2002). Thus, practices are indexical because they are 
not completely comprehensible outside the context in which they are created and 
used (Gherardi 2009, Gherardi 2008). In the article, The Bridge – connecting science 
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and business, I examine activities that connect science and business (Smircich 1983) 
and how those two communities are able to collaborate and (re)negotiate shared 
understandings. In conducting this examination, I adopt George Simmel’s theory 
of culture (Frisby 2002, Frisby and Featherstone 1997, Simmel 2004), and, more 
specifically, I adopt his concept of the bridge as a theoretical concept. In the article, 
my focus is on everyday work and all the various activities it entails. I also focus 
on the creation of a boundary object, the business plan, which helps ideas and 
understandings to traverse boundaries (Gherardi 2012, Carlile 2002).
To fully comprehend biotechnology marketing practice, it is also necessary 
to understand the specific setting in which these companies operate. The arti-
cle Anticipating and Managing Challenges in Biotechnology Marketing focuses on the 
industry-level setting in which biotechnology marketers operate. As discussed 
above, scientific rationalism generates simplistic theories that may not be valid 
in any particular context. The practice-based approach holds that markets are 
constructed and shaped by multiple practices implemented by different actors, 
including companies and customers, rather than being generalised, pre-defined 
structures (Slater 2002, Araujo et al. 2008, Kjellberg & Helgesson 2006). In this 
article, I employ one of the central frameworks for marketing in technology-in-
tensive industries and examine how the distinct features of biotechnology affect 
that framework’s applicability in the biotechnology industry. In contrast with the 
general approach to marketing, I focus on the issues that both make biotechnol-
ogy markets special and make general marketing concepts inapplicable to them. 
Therefore, this article addresses the question of the specific features of the setting 
in which biotechnology companies operate.
In the article “Biotechnology marketing: Insider and outsider views”, written with 
Päivi Eriksson, we focus on the activities of biotechnology practitioners in small 
companies. We investigate biotechnology marketing as it is defined, performed 
and organised in biotechnology companies. The research is based on a novel meth-
odological concept that combines insider and outsider perspectives. The outsider 
view focuses on the generalised formulations of researchers, whereas the insider 
view refers to the understandings of the practitioners themselves (Laukkanen 
& Eriksson 2013). In the article, we begin from an emic (insider) perspective to 
examine practitioners’ efforts from their own point of view. Then, we combine 
the insider perspective with the outsider (researchers’) perspective of marketing 
activities in biotechnology companies. Combining these two perspectives results 
in a deeper understanding of biotechnology marketing practice.  
The first three articles are based on the belief that the abstract and general 
a priori truths of marketing (Tapp & Hughes 2008) cannot explain the activi-
ties, interpretations and understandings of the practitioners involved in practice 
(Laukkanen & Eriksson 2013, Gherardi 2008). However, according to Nicolini 
(2013, 14), “the attention on activity and the doing are only a departure point, a 
sort of ticket that grants entry to a novel world”. In the last article, “Science market-
ing practice of a biotechnology start-up”, written with Päivi Eriksson, we apply the 
practice theoretical framework to analyse how small biotechnology companies 
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engage in the practice of marketing. We understand practice as shared and rou-
tinised bodily behaviours that involve a shared conception of how things are 
done (Gherardi 2012, Nicolini 2013, Reckwitz 2002). Practices consist of several 
interconnected elements, including how the activities in question are performed 
and how certain objects are addressed (e.g., knowing how to do something or how 
to understand the world) (Reckwitz 2002, Nicolini 2013). Practices are shared and 
routinised behaviours that involve a shared conception of how things are done 
(Reckwitz 2002, Whittington 2006).
1.3 MY POSITION 
Although my aim from the outset of this study has been to closely examine bio-
technology marketing with an appreciation for practitioners’ views of their work, 
I began this study as a researcher examining the phenomenon from afar—and as 
an outsider—because the biotechnology industry was not easily accessible. Before 
I was able to engage with practitioners at the level of everyday work, I had to learn 
the vocabulary and understand the business and context in which companies 
operate to be able to communicate with practitioners. Accordingly, my first two 
articles that focus on the biotechnology business and the setting in which com-
panies are embedded illustrate the ends of the continuum: as a complete outsider 
and then as a member of the group under study. 
The third article, written with Päivi Eriksson, is based on the notion that com-
bining the practitioners’ vantage point (the emic perspective) with that of outsid-
ers or researchers (the etic perspective) is a fruitful starting point for a study (Agar 
2007, Douglas & Craig 2006). The combination of outsider and insider views not 
only accounts for meanings in the socio-cultural context of the biotechnology 
business but also considers the practitioners’ view in relation to broader theoreti-
cal knowledge. In the third article, we were outsider researchers in an effort to 
understand the phenomenon from the practitioners’ perspective. In the last article, 
my position shifted, as I was part of the group under study. In the last article, we 
do not merely attempt to grasp the insiders’ view of biotechnology marketing. 
Instead, our aim is to advance the research using a narrative analysis in an at-
tempt to present the phenomenon in a way that allows the reader to have a sense 
of how everyday marketing functions in small biotechnology companies and how 
marketing practice thus begins to emerge.
1.4 KEY CONTRIBUTION 
This study contributes to the small business and biotechnology marketing litera-
ture by providing insights on marketing practitioners’ work in the context of the 
biotechnology business. Describing marketing from a practice perspective pro-
vides a rich and comprehensible picture of how marketing is performed in small 
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biotechnology companies. The study highlights how the historical, cultural and 
technological aspects of the industry affect the small companies that operate in 
the industry and how these companies engage in marketing. 
This study also demonstrates that the “marketing-as-practice” (Skålen & 
Hackley 2011) approach is a useful framework in which to study marketing in bio-
technology companies. The practice-theoretical framework enables an alternative 
view of biotechnology marketing to be formulated that is more multi-dimensional 
than the traditional, generalised conception of such marketing. 
This study reveals how the insights generated from this line of inquiry have 
the potential to extend the concept of marketing and provide relevant and valuable 
insights for both marketing theory and practice (Srinivasan 2008, Stemersch & Van 
Dyck 2009, Eriksson & Rajamäki 2010). This study broadens the concept of mar-
keting by introducing science marketing as a new type of marketing. Specifically, 
this study’s results illustrate how the routines of scientific work are transferred to 
a science-based start-up company and eventually combine with more traditional 
marketing practice to create science marketing, which is fundamentally different 
than the marketing that is described in the literature. Science marketing occurs in 
the dual context of science and science business and is a practice in which scientific 
work and traditional marketing interact in a specific manner.
The theoretical contribution of this study is that it demonstrates that scientific 
work and the competences developed in academia are essential elements in sci-
ence marketing; this theoretical contribution also demonstrates how such scien-
tific work and academic competences can be integrated into everyday marketing 
work in biotechnology companies. The practical contribution for entrepreneurs 
and managers of small biotechnology companies is to show that combining aca-
demic expertise and the routines developed in academia with more traditional 
marketing methods and techniques is a valid and fruitful way of engaging in 
marketing practice. 
1.5 THE STRUCTURE OF THE INTRODUCTORY ESSAY
The remainder of this introductory essay is organised as follows. First, I will as-
sess the previous literature on biotechnology marketing. Then, I will discuss the 
characteristics of the biotechnology industry and the companies that operate in it. 
Next, I will discuss the previous literature on biotechnology marketing.
In the third chapter, I discuss practice theory and the theoretical and philo-
sophical underpinnings of each article in my dissertation. In the fourth chapter, I 
describe the process employed to collect the empirical data and provide a detailed 
description of how I used and analysed the data in each article. In chapter six, I 
present a brief summary of the three articles and one unpublished manuscript 
comprising my dissertation. Finally, I provide a brief discussion and the conclu-
sions of my dissertation and present avenues for further study.
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2 Biotechnology business 
and marketing 
I soon realised that it was challenging to have a meaningful conversation with the biotech-
nology practitioners. It was not that they were unwilling to cooperate, but we did not know 
how to talk to one another. At first, I tried to conduct telephone interviews:
Me: How is your company doing marketing?
The respondent: I do not understand the question.
That was essentially the content of my first interview. I was so taken aback by the fact 
that he did not understand the word “marketing” that I was left speechless and could not 
formulate a single clarifying question. However, this ”failed” interview only increased my 
curiosity: Why did he not recognise the word? Could it be that they really do not engage 
in any marketing? Do they not know how to do it? Or are they doing it but simply with 
another word in place of “marketing”? Above all, I wanted to kick myself for being so 
short-sighted to think that a concept that is so common in marketing textbooks would be 
self-evident to people operating in an entirely different social context.      
 
2.1 BIOTECHNOLOGY AS A SCIENCE-BASED BUSINESS
The biotechnology industry is made up of both large and small companies that ap-
ply biotechnology techniques to produce goods and services, in addition to other 
companies that employ such technologies, applications and products in their own 
business. This study focuses on small biotechnology companies. 
By the 20th century, the formerly separate worlds of science and business had 
begun to converge (Pisano 2010). In 1980, the United States passed the Bayh-Dole 
Act, which has been regarded as the catalyst for the growth of the biotechnology 
industry because it allowed universities to retain the rights to the research con-
ducted in their labs and provided such academic facilities with the incentive to 
commercialise research knowledge. Since then, it has been possible for academics 
to establish companies while retaining their academic positions, and interaction 
and information flows between academic research and business development 
have grown (Prevezer 1997). During the 1990s, Europe grew to accept spinning 
off new ventures from academic labs as a valid method of technology transfer 
(Degroof & Roberts 2004). University spin-offs and licensing are the most com-
mon means of commercialising the results from research conducted in university 
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laboratories (Wood 2009, Wright et al. 2009, Pirnay et al. 2003). This development 
resulted in new organisational forms, science-based companies that create and 
apply basic science for financial profit (Pisano 2010). The majority of biotechnology 
companies are small companies, established and led by scientist-entrepreneurs to 
commercialise their academic work (Tahvanainen 2004, Lehrer & Asakawa 2004, 
Jonsson 2007, Cetindamar & Laage-Hellman 2003, Nicolau & Birley 2003). These 
small biotechnology firms have played an important role in developing bio-phar-
maceuticals and have served as intermediaries for information to flow between 
the basic research conducted at universities and commercial exploitation by large 
pharmaceutical firms (Roijakkers & Hagedoorn 2006).
Biotechnology includes business sectors such as the pharmaceutical, agricul-
ture, chemical and medical device industries (Hall & Bagchi-Sen 2007). In Europe, 
dedicated biotechnology companies, i.e., companies that produce products or ser-
vices using biotechnology techniques (OECD 2005), employ approximately 96,000 
individuals; the impact of these companies spans several industrial boundaries 
because biotechnology companies collaborate with other industries, such as the 
pharmaceutical and chemical industries, that utilise biotechnological applications 
(Jonsson 2007). 
The majority of companies in the biotechnology industry are young and small 
(Critical I). According to the EuroBiotechMonitor Survey, 86% of European bio-
technology companies have 1-5 employees (EuroBiotechMonitor 2012). The small 
size of new technology-intensive companies, such as biotechnology companies, 
increases uncertainty with respect to commercial success. In the early phases of 
the industry life cycle, smaller companies fail more often than larger companies 
(Agrawal & Audretsch 2001). Many of these young and small companies face chal-
lenges accessing financial and human resources (Delorme et al. 2005) that are 
necessary to run their operations efficiently. Despite these challenges, most bio-
technology companies generate, and operate on, their own revenues. By the end 
of 2004 in Europe, there were 2163 biotechnology companies that generated €21.5 
billion in revenue. By contrast, the US biotechnology sector has 1991 companies 
but generated €41.5 billion in revenue (Critical I).
Small science-based biotechnology companies and larger incumbents have dif-
ferent but complementary capabilities, which may explain why the biotechnology 
industry is highly networked (Madhok & Osegowitch 2000). Small biotechnol-
ogy companies tend to focus on upstream capabilities: they focus on meeting the 
milestones specified in licensing deals and leave marketing and commercialisa-
tion issues to their downstream partners (Renko 2006). Moreover, they are much 
more cost efficient in, for example, the production of new medical entities than 
large pharmaceutical companies (Munos 2009). Small biotechnology companies 
collaborate with incumbent companies (Madhok & Osegowitch 2000, Niosi 2003), 
university technology transfer offices and government-funded commercialisation 
programmes (Debackere & Veugelers 2005, Siegel et al. 2004). These collaborations 
help these smaller companies overcome their lack of downstream capabilities 
(such as resources and capabilities in manufacturing, clinical testing, regulatory 
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approval), access marketing and distribution channels (Bagchi-Sen 2007, Madhok 
& Osegowitch 2000), gather knowledge from foreign markets through their part-
ners (Yu et al. 2011, Wuyts & Dutta 2008), develop their businesses and acquire 
market knowledge (Renko 2006). 
Another feature that distinguishes biotechnology from other industries is the 
profound technological uncertainty that is currently even greater than in the early 
days of the industry. The pioneering biotechnology companies relied on new pro-
duction methods that were based on molecules, the functions and mechanisms 
of which were already known well (Prevezer 1997, Pisano 2006). The novelty of 
these innovations was that they altered the patterns of production, for example, by 
using recombinant DNA technology and other biotechnological manufacturing 
technologies (Robertson & Gatignon 1986, Fazeli 2005). Therefore, such early pio-
neers were not subject to risks as substantial as those that biotechnology compa-
nies face today (Fazeli 2005). In today’s market, companies pursuing new product 
innovations face considerably higher risks: approximately one out of 6000 newly 
synthesised compounds makes it to the market. Nonetheless, scientists must make 
decisions regarding the pipeline optimisation period before there is any certainty 
with respect to how a particular molecule will work (Stemersch & Van Dyck 2009, 
Pisano 2006). 
The rapid pace of technological development and the industry’s technological 
origins in complex science make company networks in biotechnology differ from 
those in other industries (Powell et al. 1996). The first difference is that biotechnol-
ogy companies tend to source new knowledge from a greater variety of sources 
than companies operating in other industries (Plum & Hassink 2011). Second, 
biotechnology companies are more likely to cooperate in R&D than other com-
panies or government institutions, and such partners are more likely to be inter-
national than those in other industries (Holl & Rama 2012, Hopkins et al. 2007). 
Biotechnology companies are also more likely to engage in open innovation (Holl 
& Rama 2012). These characteristics demonstrate that the industry’s origins in sci-
ence affect both knowledge acquisition and the nature of their networking efforts.
2.2 SMALL BIOTECHNOLOGY COMPANIES AND ENTRE-
PRENEURS
Although the emergence and characteristics of the biotechnology industry have 
been well researched, prior studies have exhibited less interest in the company-
level characteristics of firms operating in the industry. Thus, little is known about 
the factors related to academics founding start-ups, not only in biotechnology but 
also in general (Shane 2004, Lockett & Wright 2005). Academics are not particu-
larly entrepreneurial in nature (Rodgers et al. 2002) and are not particularly eager 
to establish a rapidly growing business (Meyer 2003). 
For academics, a new venture may not necessarily be established on entrepre-
neurial aspirations; it may simply represent another way to continue academic 
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research and enhance their academic careers (Fini et al. 2009, Lehrer & Asakawa 
2004). In their study of Italian academics, Fini et al. (2009, 398) found that the mo-
tivation to found a company was related to the expected academic (rather than 
economic) outcomes, i.e., “the generation of further stimuli for research activities, 
the gain of prestige and reputation as leading academics, the creation of funding 
opportunities (grants) for students or research assistants, or the possibility to get 
new infrastructure and facilities for academic research activities”. Therefore, it is 
not surprising that when scientists become entrepreneurs, they mainly continue 
in the role of scientist, and commercial activities have lower priority (George et 
al. 2005), which creates problems when academic goals conflict with the economic 
goals of their parent organisations, venture capitalists and/or other stakeholders 
(Vohora et al. 2004, Samson & Gurdon 1993) who may demand a more market-
oriented focus (Hermans et al. 2004). In addition, academics’ strong self-belief and 
self-centred personalities, which may be an advantage in the academic context, 
make it challenging for academics to work with venture capitalists or understand 
customer needs (Yim & Weston 2007). The problem with studies that present sci-
entist-entrepreneurs as inferior and in some way lacking is that they are based on 
a predefined theoretical conception that depends on the notion that ideal entrepre-
neurs are similar across industries. Previous studies do not consider the specific 
features of the biotechnology business or the settings in which companies operate, 
although such features may affect the type of personalities and motivation that 
are appropriate for the biotechnology business. 
2.3 BIOTECHNOLOGY MARKETING
Because many biotechnology companies are small and operated by scientist-
entrepreneurs, they face challenges in accessing financial and human resources 
(Delorme et al. 2005). These challenges naturally affect several areas of operations, 
including marketing. 
Although scientist-managers are experts in academic research, they may be less 
knowledgeable and experienced in business matters and lack the skills required to 
operate a business (Samson & Gurdon 1993, Kinsella & McBrierty 1997, Franklin et 
al. 2001,Hermans et al. 2004, Hermans & Luukkonen 2002). For example, studies by 
Hermans et al. (2004) and Hermans & Luukkonen (2002) reveal that biotechnology 
companies have low shares of full-time or part-time marketing personnel. These 
same studies also demonstrate that the typical Finnish small biotechnology com-
pany’s chief executive officer has 10 years of experience in business, and some of 
the company’s personnel possess marketing expertise. Moreover, a small number 
of companies had no marketing experience. Based on these results, these stud-
ies concluded that biotechnology companies in general lack marketing expertise. 
The problem with these studies is that they are based on traditional concepts of 
marketing and do not consider the possibility that marketing functions may not 
be organised separately in the biotechnology business. As Hagberg & Kjellberg 
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(2010) note, the general assumption that there would be a distinct marketing pro-
fessional has proven questionable. Moreover, Yim & Weston (2007) use a general-
ised conception of the entrepreneurial personality type as a starting point in their 
study of the personal characteristics of scientist-entrepreneurs. Without consid-
ering industry-specific factors, these authors conclude that the biotech industry 
requires personality types that are highly customer-oriented, sociable and eager 
to understand customer needs and find ways to meet them. 
In addition to research on marketing competence, the literature has focused on 
the alliances and social networks of biotechnology companies and their founders. 
To compensate for their lack of marketing resources and skills, many biotechnol-
ogy companies form alliances with established companies in the industry (Bas & 
Niosi 2007). Small biotechnology companies use alliances to access marketing and 
distribution channels (Bagchi-Sen 2007) and to gather market intelligence about 
foreign markets through their partners (Yu et al. 2011, Wuyts & Dutta 2008). The 
evidence reveals that alliances are related to higher rates of growth and revenue 
(Baum et al. 2000) and foreign sales (Yu et al. 2011). Such alliances are frequently 
based on the social networks of the founders, who channel knowledge, expertise 
and information between the firm and their social network; thus, the founders 
connect the firm to a wider range of expertise (Grandi and Grimaldi 2003, 2005, 
Murray 2004, Shane and Stuart 2002). 
Prior research further indicates that the majority of academics have contacts 
only within the academic community; therefore, the founding teams complement 
academics with associates and assistants with connections in the business world 
and with the customer base (Clarysse and Moray 2004, Grandi & Grimaldi 2003, 
Vohora et al. 2004). Apart from Clarysse and Moray (2004), these studies are either 
survey-based or rely on quantitative, archival statistical data. Consequently, the 
aim of these studies is to investigate the relationships between quantitative facts. 
For example, studies on alliances simply record whether alliances exist but do not 
indicate how they come into existence, how they evolve and the content of those 
alliances. In addition, those studies do not account for the science-business link-
age in biotechnology and therefore may focus on business customers and fail to 
appreciate the importance of broad contacts in academia.
Third, recent research touches on issues related to strategy. By contrast to 
Hermans et al. (2004) and Hermans & Luukkonen (2002), Hall et al. (2007) consider 
the percentage of marketing personnel to indicate a firm’s strategic choice rather 
than marketing skills and find that biotechnology firms with relatively higher 
levels of R&D intensity employ strategies that can be summarised as an align-
ment with industry. Firms with relatively lower R&D intensities employ strate-
gies that focus on competitiveness, marketing and distribution channels. These 
findings are compatible with studies by Chakrabarti & Wiesenfeld (1989, 1991), 
who conclude that biotechnology companies reduce risk by focusing on either 
technology or marketing. Companies that are highly R&D intensive and possess 
radical technological innovations follow conservative marketing strategies and 
vice versa. Importantly, these studies are based on counting quantifiable observa-
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tions and the notion that companies consist of separate functionalities. Personnel 
who participate in both R&D and marketing may go unnoticed or be mistakenly 
classified in one function only.
Few studies in the biotechnology marketing literature focus on how companies 
actually engage in marketing. Costa et al. (2004) investigate the marketing process-
es of Portuguese biotechnology companies and explored whether these companies 
follow the basic procedures that theory suggests are involved in an appropriate 
marketing process: the definition of strategic marketing, marketing implementa-
tion and the evolution of strategy and implementation. Their study reveals that 
companies in which the entrepreneurs or directors had a research background 
experienced difficulties in marketing, in particular, which were related to a lack of 
both managerial and marketing capabilities, and the main problem concerned de-
fining the scope of the business. Furthermore, this study finds deficiencies in stra-
tegic marketing and marketing implementation in areas such as market research, 
identification of competitors and specific customer needs and product differen-
tiation and positioning. The study concludes that marketing-related deficiencies, 
in particular, might explain the lack of commercial success in the biotechnology 
sector and further asserts that biotechnology companies face serious difficulties 
in the marketing process because they lack a clear market-oriented focus and the 
commercial sense and skill necessary to orient the company toward the market. 
These authors compare their study’s findings to information from other industries 
and the generic concept of marketing and find that biotechnology companies do 
not seem to follow generic marketing procedures and concluded that their efforts 
were inadequate. 
Renko (2006) accounts for the specific features of the biotechnology business 
and their bearing on biotechnology marketing. When assessing the marketing 
orientation of biotechnology entrepreneurs in the US, she finds that although bio-
technology firms may exhibit market-oriented behaviours, these behaviours are 
not similar to the types of market-oriented behaviours suggested in the market-
ing literature. She suggests, in particular, that young and small biotechnology 
companies may differ from other companies that are otherwise similar because 
they are not ‘naturally’ exposed to market knowledge during their first years of 
operation. She provides two reasons for this phenomenon: first, young and small 
biotechnology companies may focus exclusively on science-driven R&D activities, 
and second, such companies do not have any products on the market during their 
first years of operation. For example, market intelligence in biotechnology SMEs 
often emerges as a ‘by-product’ of other information exchanged within a network 
of companies. It is not considered a high priority and is pursued less formally 
than traditional means of gathering market intelligence through customer surveys 
and meetings with trade partners and customers, among other means. However, 
companies assess their potential markets through various informal means by con-
sulting opinion leaders, peers and universities (Renko et al. 2005). The findings 
of Renko et a. 2005 and Renko 2006 raise questions regarding whether there are 
deficiencies in the marketing competence of biotechnology companies or whether 
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biotechnology marketing remains unidentified by the research approaches, meth-
odologies and data used in earlier studies. 
In conclusion, previous research on biotechnology marketing is largely based 
on a traditional, general concept of marketing. In this study, I argue that the spe-
cific characteristics of different businesses create unique challenges for marketers 
and must be accounted for (Stemersch & Van Dyck 2009) to obtain a more com-
prehensive picture of biotechnology marketing. In particular, the dual context of 
science and business requires exploration. I further argue that the approaches 
that compare quantifiable observations to the a priori truths of marketing theory 
are not able to provide a comprehensible and accurate picture of biotechnology 
marketing. Instead of theory, approaches that focus on how marketing is actually 
conducted in these companies and appreciate the practitioners’ perspective are 
necessary to provide a richer understanding of this phenomenon.     
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3 Practice theoretical 
framework 
While conducting this study, I attended several conferences to present my preliminary 
findings and unfinished ideas. An interesting incident transpired when I wanted to find a 
way to present my ethnographic research results—which eventually became the article “The 
Bridge – connecting science and business”—in a way that would make my experience easily 
accessible to the audience. I presented my results as a brief animated film that I made on a 
computer. After the final credits and music had faded, the room erupted in chaos. Many of 
the more reputable academics were extremely agitated. Some of the young entrepreneurs 
attempted to say that the film realistically described issues that they had experienced when 
founding a company. Nevertheless, those of us who had direct experiences with entrepre-
neurship were harshly silenced. “You do not know anything about entrepreneurship”, one 
of the professors in the audience roared at me. Such excessive reactions made me wonder 
why these academics were not interested in what occurs in real life. Why would they privi-
lege theories that may have only little to do with reality?
3.1 MARKETING AS PRACTICE
It is worth noting that many authors publishing in marketing journals in the 1950s 
and 1960s were practitioners (McKenzie et al. 2002). However, recent research 
reveals that the majority of contemporary practitioners are unaware of academic 
journals, let alone read them (Reed at al. 2004, McKenzie et al. 2002). Moreover, the 
gap between marketing theory and practice is actually much wider: practitioners 
regard marketing research as inappropriate or unusable (Reed et al. 2004, Tapp 
& Hughes 2008); practitioners believe that the constructs that academics theorise 
about cannot be found in real life (Ardley 2008b, Edwards 2005, Hackley 2001), 
and researchers are unaware of what marketing practitioners actually do (Easton 
2000). This clearly indicates that a new approach is required to refocus marketing 
research and make it more relevant to the organisational reality faced by prac-
titioners (Brennan & Ankers 2004, Robson & Rowe 1997). As McCole (2004, 531) 
notes: “It is high time that academic community adopts an inductive approach so 
as to understand how marketing is carried out in practice.”
In social sciences, interest in studying working practices, the ”practice turn”, 
began to gain momentum in the 1980s in organisation studies (Corradi et al. 2010, 
Whittington 2006). The roots of the practice turn, however, can be traced to the 
previous decades in the studies of theorists such as Pierre Bourdieu, Michel de 
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Certeau, Michael Foucault and Anthody Giddens, who share an interest in the 
cultural rules and norms that guide human activity, the detailed exploration of 
how activities are performed and an appreciation of practitioners as “artful inter-
preters of practices” (Whittington 2006, 615). The practice turn is also indebted to 
Alfred Schutz and Harold Garfinkel and their notion of an intersubjective world, 
which means that although each individual has a different perception of reality, 
those individuals interact and share meanings that, in turn, give rise to a shared 
understanding of how to perform certain tasks or how to interpret the world 
(Gherardi 2008).
The practice turn includes a wide range of diverse streams of literature. 
Orlikowski (2010) classified these streams by their conception of practice as one of 
the following: a) phenomenon, b) perspective or c) philosophy. Corradi et al. (2010) 
classified the streams of research by whether the practice is treated as an “empirical 
object” or as a “way of seeing”. Moreover, Geiger (2009) classified the literature into 
two groups, one focusing on routines and the other using practice as an “epistemic-
normative” perspective. Nicolini et al. (2003) distinguish four practice-based ap-
proaches: the interpretive-cultural approach, the community of practice approach, 
the cultural and historical activity theory approach and actor network theory. This 
multiplicity of practice-based approaches indicates that the practice turn consists 
of a remarkable variety of ways of understanding action. These typologies demon-
strate how the practice turn actually consists of a remarkable variety of different 
research streams. Accordingly, the concept of practice varies from common-sense 
conceptions of practice to rigorous formulations (Corradi et al. 2010).
Studies focusing on what marketing practitioners do in practice may or may 
not employ the theoretical concept of practice, but such studies nevertheless focus 
on the activities of marketing practitioners. These include studies by Feldman & 
McNeilly 2003, Gilmore et al. 2001, Eriksson & Rajamäki 2010, Brodie et al. 1997, 
Lien 1997, Prus 1989, Brown 2005, Coviello et al. 2000, von Koskull & Foughere 
2011 and Järventie-Thesleff et al. 2011. In these studies, the focus is not on what the 
organisation possesses (skills, experience, etc.) but on what the members of that 
organisation do and how they engage in marketing. Another stream of practice 
studies on marketing have focused on market practice. These studies posit that 
markets are not self-contained static entities but are instead constructed through 
the various and frequently conflicting practices of different actors. These studies 
include articles by Callon 1998, Finch & Acha 2008, Andersson et al. 2008 and 
Kjellberg & Helgesson (2006, 2007). The practice-oriented literature on consumer 
research has studied consumption practices and how consumers realise or cre-
ate value through various practices. Practice-oriented consumer studies include 
Warde 2005, Holt 1995, Cochoy 2008, Korkman 2006, Brownlie & Hewer 2011, 
Fellesson 2011 and Schau et al. 2009. 
In this study, I employ the concept of practice in a variety of modes. In the fol-
lowing, I will discuss treating practice as phenomena and practice as a theoretical 
framework because that division is the most helpful in illustrating the theoretical 
commitments contained in the articles in this study.
26 27
3.2 PRACTICE AS PHENOMENA 
Many authors believe that the origin of the gap between marketing researchers 
and practitioners is found in the positivistic or logical empiricist approach (Tapp & 
Hughes 2008, Ardley 2008, Arndt 1985). In mainstream marketing research, com-
plex and continuously evolving phenomena have been abstracted into universal 
theories and a priori truths that are then measured with simplified statements 
(Tapp & Hughes 2008, Ardley 2008). Marketing actions in organisations are then 
examined to determine whether they conform to or deviate from theory (Ardley 
2008). This approach does not appreciate practitioners’ perspectives on their own 
work; instead, it treats practitioners as subjective and biased, although researchers 
are considered unbiased and capable of producing validated knowledge (Sandberg 
& Tsoukas 2011). The problem with this approach is that it removes knowledge 
from its social context and generates highly simplistic propositional statements 
that are not valid in any particular context (Sandberg & Tsoukas 2011, Svensson 
2007). Theories generated in this manner have little to do with what practitioners 
experience in reality, as Arndt (1985) posited: “Overemphasis on formal represen-
tations of knowledge may result in empirically empty formal structures irrelevant 
to the problems” (Arndt 1985, 13).
The practice-based approach builds on the belief that theories of organisations 
do not reflect what actually occurs in organisations and clearly distinguishes be-
tween “what actually happens and what researchers claim to happen through 
their representations, frameworks, narratives, models, propositions and theories” 
(Orlikowski 2010, 24). Nicolini (2013) calls this approach the weak practice-based 
programme because it stresses devoting attention to everyday work without 
adopting a specific theoretical conceptualisation of practice. The weak programme 
includes various conceptualisations of practice that include practice as “what ac-
tors do” (Geiger 2009), “practice as phenomena” (Orlikowski 2010) or “practice as 
empirical object” (Corradi et al. 2010). The conception of practice entails all types 
of activities, routine and non-routine, formal and informal, central and peripheral 
(Whittington 2006).
The theoretical bases for studies adopting the weak programme may vary, 
but they all share “a specific commitment to understand what practitioners do ‘in 
practice’, with practice here signifying practical activity and direct experience” 
(Orlikowski 2010, 23-24). The majority of practice-based marketing research fo-
cuses on practice as phenomena and is thus interested in the activities of mar-
keting practitioners. The aim of these studies is to more closely approximate the 
practitioners’ lived experience and explore what practitioners actually do in their 
particular field of practice (Corradi et al. 2010, Orlikowski 2010). In so doing, re-
search can produce knowledge that more accurately reflects the lived reality of 
practitioners in a given field and is thus also more relevant for different practi-
cal situations (Geiger 2009). Therefore, I believe that adopting a practice-oriented 
research approach and focusing on what actors do is a fruitful solution to the 
problem of relevance in marketing research.
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3.3 PRACTICE PERSPECTIVE OF THIS STUDY
The practice-as-phenomena approach is interested in identifying and recording 
individuals’ various routines and activities (Nicolini 2013, Geiger 2009), and the 
conceptualisation of practice encompasses all types of activities, both routine and 
non-routine (Whittington 2006). By contrast, the practice-as-theoretical-framework 
approach treats practice as an analytical concept “through which to understand 
organizations, examining the recurrent doings and saying of actors and how those 
are shaped by and shape structural conditions and consequences” (Orlikowski 
2010, 29) Thus, under the latter approach, the concept of practice is used not only 
to describe working life but also as a theoretical lens to explain organisational 
matters (Nicolini 2013). Although “practice as theory” is not a unified theoretical 
framework, the different streams of literature share certain principles.
Practices are molar units, which means that they are constellations of smaller 
elements, such as actions, objects, knowledge and bodily motions (Nicolini 2013, 
Schatzki et al. 2001, Schatzki 2006, Reckwitz 2002). However, there are various 
opinions about which elements constitute practice. According to Schatzki (2006), 
the basic components of practice are action and structure. Structure consists of 
several interconnected elements, including knowing how to perform certain tasks, 
explicit rules and directions, affective structuring, and a general understanding 
of the nature of the work and how it should be performed. Alternatively, accord-
ing to Reckwitz (2002), the elements of practice include bodies, minds, objects, 
knowledge and discourse. In the following, I will describe the main elements that 
I believe constitute a practice.
Practice theory accords a central position to the human body (Reckwitz 2002). A 
practice is a routinised and skilful way of using the body (Reckwitz 2002, Nicolini 
2013). The knowledge required to learn to use the body in a skilful way (e.g., to 
participate in a practice or further refine a certain practice) is sensory and kinaes-
thetic knowledge (Amin & Roberts 2008, Gherardi 2008) that is acquired when 
novice practitioners employ their senses by watching, listening and touching 
while learning the practice (Gherardi 2012, Strati 2007). Gherardi (2012, 74) notes: 
“Not only people work through their bodies, they also know with their bodies, 
and the knowledge thus acquired is conserved in their bodies”. Thus, a practice 
recalls handiwork or a craftsman’s skills: the knowledge necessary to learn or to 
refine a certain practice is not acquired mentally but is acquired through the entire 
body by means of the five senses (Amin & Roberts 2008, Gherardi 2008). Novice 
practitioners learn by watching, listening and touching while learning the prac-
tice (Gherardi 2012, Strati 2007). Knowledge is not created by applying certain a 
priori truths; instead, knowledge is generated in the situations in which it will be 
used (Gherardi 2008). Therefore, practices are organised around shared practical 
knowledge regarding the tasks and activities at hand (Nicolini et al. 2003).
The second element is mind. In contrast with other cultural theories, when 
referring to the mind, Reckwitz (2002) does not refer to something deep inside an 
individual that dictates how the individual behaves (i.e., mentalism) or a mind that 
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has internalised rules imposed from outside (i.e., intersubjectivism). In practice 
theory, mind refers to a shared and routinised way of understanding the world 
(Reckwitz 2002, Nicolini 2013). Reckwitz (2002) calls these routinised understand-
ings mental patterns that include rules about how to behave in certain situations, 
what is right and wrong and the accepted or desired emotions in certain situa-
tions (Reckwitz 2002, Nicolini 2013). To undertake a skilful bodily performance, 
one must have expertise on how to perform the practice and an understanding of 
what would be the successful or desired outcome. For example, flute makers share 
an understanding of how the perfect flute feels and sounds (Cook & Yanow 1993). 
That understanding is connected with the bodily performance of craftsmanship 
in making a perfect flute. 
The third element is knowledge. According to Reckwitz (2002, 253), “in a prac-
tice the knowledge is a particular way of understanding the world”. Practices 
contain shared understandings of the world and how certain tasks should be 
performed (Gherardi 2012, Reckwitz 2002). When practitioners perform a practice 
in specific situations, they create collective and shared knowledge that is not eas-
ily understandable outside the particular situation in which the knowledge was 
originally created and employed (Reckwitz 2002, Gherardi 2008, 2009). Moreover, 
this knowledge includes the understanding to perform the practice and the abil-
ity to interpret the behaviours of others who are engaged in the same practice 
(Gherardi 2012, Reckwitz 2002). Knowledge, i.e., a shared understanding of how 
things should be done, is produced and reproduced when practices are performed 
in specific situations (Gherardi 2012, 2008, Reckwitz 2002). 
The fourth element is objects. Reckwitz (2002) emphasises material objects, 
such as computers, files and phones, as essential components of practices. To play 
football, players require a ball. To conduct polymerase chain reaction amplifica-
tion, the scientist needs, among other things, cylinders, pipettes and a microwave. 
Therefore, objects are “things to be handled and constitutive elements of forms 
of behaviour” (Reckwitz 2002, 253), which indicates that objects are the tools and 
appliances required to perform a certain routinised behaviour (Nicolini 2013, 
Reckwitz 2002). Gherardi (2012) uses the study of Grosjean & Bonneville (2009) 
to illustrate how objects anchor practices in time and incorporate representations 
of knowledge produced in the past. Handbooks, calendars and models that are 
part of a practice assist practitioners in remembering past decisions and events 
(Gherardi 2012). When performing tasks, practitioners need objects, various types 
of tools and appliances to complete a given routinised behaviour. When a scien-
tist performs experiments in the laboratory, he may need pipettes, cylinders and 
various machines, depending on the task at hand. A marketer may need papers, 
computers and brochures. Thus, objects are “things to be handled and constitu-
tive elements” of practice (Reckwitz 2002, 253). Highly project-specific objects can 
create boundaries, whereas certain objects can facilitate interaction between dif-
ferent practitioners (Swan et al. 2007). Objects also participate in reproducing the 
social order in a certain way, such as how classroom facilities produce order in 
the class (Nicolini 2013).
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Individuals participating in the same practice constitute a community of prac-
tice (Lave & Wenger 1991) that creates and sustains the practice in the situations in 
which the practice is performed. All individuals are simultaneously members of 
several communities of practice. As Reckwitz (2002, 256) posits, “the individual is 
the unique crossing point of practices, of bodily-mental routines”. The body and 
the mind are equally necessary components of practices and together constitute 
individual agents (Reckwitz 2002). The knowledge required to perform the prac-
tice and the knowledge produced by the practice is essentially intertwined with 
both body and mind and cannot be treated separately when analysing practice. In 
practice theory, individuals are bodily and mental agents who act as carriers of a 
multitude of practices (Reckwitz 2002). The groups of individuals who participate 
in the same practice are termed communities of practice (Lave & Wenger 1991), 
which emphasises that routines are social and situated. Communities of practices 
share practical activities among the individuals in that community (Corradi et al. 
2010). 
Practice theory locates the structure of action in the routinised constella-
tions of smaller elements that constitute a practice (Nicolini 2013, Reckwitz 2002). 
Reckwitz (2002) employs the concepts of “praxis” and “praktik” to illustrate the 
difference between routine and non-routine behaviour. Practice (praxis) in the 
singular form refers to various types of activities, both routine and non-routine 
(Whittington 2006). By contrast, practices (praktik) refer to shared and routinised 
behaviour and involve a shared conception of how things are done. Praxis en-
tails individual, non-routine actions, whereas practices (praktik) are molar units 
(Nicolini 2013) that consist of several interconnected elements. These elements 
include understandings of how the activities in question are performed and how 
certain objects are handled (e.g., knowing how to do something or how to under-
stand the world) (Reckwitz 2002). Practice (praxis) may also consist of a multitude 
of activities, but compared to practices (praktik), the constellations of non-routine 
activities are fragmented and inconsistent and thus lack a shared understanding 
of the world (Nicolini 2013). The social structure is sustained when performing 
a practice. Accordingly, social structures are changed when practices are refined 
and fine-tuned every time they are undertaken (Gherardi 2008) or when practices 
must be changed in response to a crisis (Reckwitz 2002). 
Because practices contain specific, collective and shared knowledge, they are 
not completely understandable or easily transferable outside the context in which 
they were created and used (Reckwitz 2002, Gherardi 2008, 2009). Moreover, 
changing or transferring a practice is a complex process that consists of several 
stages (Szulanski 1996). According to Szulanski (1996), these stages are initiation, 
implementation, ramp-up and integration. The initiation stage includes all events 
that lead to the decision to transfer a practice or routine. Those events could be an 
unsatisfactory current situation or the discovery of superior way of doing things. 
The implementation stage begins when the decision to transfer is being made 
(Szulanski 1996). In this phase, the information and resources flow across the 
boundaries of different communities of practitioners. Individuals acting as bound-
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ary spanners or certain artefacts that act as boundary objects are essential at this 
stage. In their study of nanotechnology-related business, Casati & Genet (2013) de-
scribe the role of a specific type of individuals, principal investigators, in transfer-
ring practices. These authors explain how engaging in different practices in vari-
ous contexts enable principal investigators to shape new trajectories by making 
sense of complex knowledge. These principal investigators also act as knowledge 
brokers among heterogeneous actors and networks. In addition to the individuals, 
the role of objects is important because of their capacity to traverse the boundaries 
of different communities (Gherardi 2012, Carlile 2002). Rajamäki (2010) show that 
the business plan of a biotechnology company acts as a boundary object because 
it contains shared language and facilitates the implementation process.
The ramp-up stage includes the initial attempts to use the new knowledge 
(Szulanski 1996). These attempts may be inefficient, and the practitioners may en-
counter unexpected problems. Routinisation occurs during the integration phase 
when the new knowledge is utilised in an effective and meaningful way. The 
routines that include the new knowledge become institutionalised and taken for 
granted in the organisation. In their study of medically assisted reproduction, 
Gherardi & Perrotta (2010) find that the stabilisation of a new practice includes 
mechanisms that limit what can and cannot be done, rhetorical closure and an-
choring in technology.  
The acknowledgement that practices, including marketing practices, have con-
sequences is another aspect that has been missing from the mainstream market-
ing literature. As Svensson (2007, 273) note about mainstream marketing research: 
“A vast array of best-selling marketing devices are offered in this literature: mar-
keting mix, promotion mix, Boston consulting group boxes, consumer behaviour 
models, positioning tricks, market segmentation bases, product life cycles and 
communication models, all of which are intended to contribute to the marketer’s 
toolbox. These tools are in the world of MMA as neutral as is a hammer or a 
screwdriver; they intervene silently upon the world, doing so without taking stand 
either for or against, only to vanish again without leaving behind any kind of 
moral judgements.” Practice theory holds that practices are situated in a context 
that is partly given but simultaneously (re)produced through the practices. Thus, 
the context has a dual nature: practices sustain and shape the organisational real-
ity in which such practices are situated (Gherardi & Perrotta 2010, Nicolini 2013). 
Gherardi & Perrotta (2010) state that “at this analytical level the researcher asks: 
what is it that doing the practice does?” Therefore, the practice-based approach 
emphasises that marketing is not value-free or without conflict; instead, practices 
always bear implications and (re)produce inequalities and privileges (Nicolini 
2013).
I believe that using practice as a theoretical framework provides a solution to 
the shortcomings of the research on biotechnology marketing that relies on the 
traditional marketing paradigm and offers a framework that can produce a richer 
understanding of—and a new way to conceptualise—marketing in small biotech-
nology companies.
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4 Study design
“I would really like to work with this professor”, I thought to myself while we were chat-
ting in a cafeteria in Finland on a cold winter day. I realised I had begun to think of these 
people as much more than the objects of my research; I considered them my friends. Would 
it be more important to help these people establish their companies and secure their em-
ployment—even at the expense of sabotaging my own study? (Rajamäki 2011, 206-207).
At times, it was difficult to balance my competing roles as researcher and member of 
the founding team, which meant being close while simultaneously attempting to distance 
myself and examine the process from further away. I wondered how to balance my roles as 
a mere observer and an active participant. How much should I influence the phenomena I 
was studying, including its grey areas and things that I would have not wanted to know 
but had to address nonetheless? I had not expected to face these types of profoundly ethical 
problems in a business study, and I had to make choices based on what felt right—not just 
as a researcher but also as a human being.
4.1 RESEARCH APPROACH AND METHODOLOGY
The conceptualisation of the nature of the elements that constitute practice is one 
respect in which approaches that apply practice as a theoretical framework are 
in striking contrast to mainstream marketing research. The positivist and logical 
empiricist roots of marketing entail the notion of representationalism (Tapp & 
Hughes 2008, Ardley 2008, Arndt 1985), which includes the belief that representa-
tions and entities to be represented are two ontologically distinct entities (Barad 
2007). In a research setting, this belief means that the new knowledge (represen-
tation), the known (the entity that is being represented) and the knower (who is 
representing) are separate and distinct entities; in addition, the scientific repre-
sentation mediates among these entities (Barad 2007). Practice theorists oppose 
representationalism, although the degree to which they do so varies with their 
onto-epistemological commitment. As Sandberg & Tsoukas (2011, 343) postulate: 
“we are never separated but always already entwined with others and things 
in specific sociomaterial practice worlds”. This position illustrates the notion of 
ontological entanglement, which means that the elements of practice are inher-
ently inseparable but that we discursively establish different components of the 
entangled phenomenon (Nicolini 2013, Barad 2007). There are hybrid associations 
that are “enacted in practice as a fluid, ongoing and contingent coproduction of a 
shared sociomaterial world” (Suchman 2007, 23). The shift from a representational 
to a performative epistemology is of central importance: “knowing does not come 
from standing at a distance and representing, but rather from direct material 
engagement with the world” (Barad 2007, 49). This direct engagement requires 
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the researcher to observe and collaborate closely with the practitioners in action 
(Orlikowski 2010).
At the outset of my study, I realised that direct engagement with biotechnol-
ogy marketing would not be a simple matter. I realised how extremely limited 
my understanding of biotechnology was and that this limited understanding was 
likely to hinder my communication with the scientists. I began to review the lit-
erature on the biotechnology industry; I read case studies and arranged several 
informal conversations with researchers involved in drug research, pharmaceuti-
cal chemistry and biochemistry to learn the basic vocabulary of the discipline. I 
also believed that I would need a context or form that would be more familiar to 
the scientists and me before I could continue my empirical explorations. Based on 
what I had learned from the case studies and articles, I wrote a conceptual article 
about biotechnology marketing. I emailed the published article to a pharmaceuti-
cal chemistry professor, who I understood to be contemplating founding a bio-
technology spin-off. I believed that the format of an article would be more neutral 
and easily accessible for both of us. I did not propose any collaboration and simply 
sent the article with a brief message that the article might interest the professor. 
Shortly thereafter, the professor sent me a message asking if I would assist with 
the creation of the new venture. We agreed that I would assist them, and in turn, 
they agreed that I could use this case in my doctoral dissertation. This was the 
beginning of my journey toward collaborating with practitioners. 
This notion of “the direct material engagement” (Barad 2007) is also reflected 
in my writing. I have written my results in a form that attempts to communicate 
the feelings I experienced to the reader directly such that the reader might experi-
ence personal involvement in the situation. Writing about research results must 
also be considered an ethical practice in the sense that researchers are responsible 
for the images they create through their writing (Rhodes 2009, Rhodes & Brown 
2005, Richardson 2000, Van Maanen 1988). The focus then shifts from represen-
tational accuracy to how the researcher constructs meaning, which is why writ-
ing must also be considered an ethical practice in the sense that researchers are 
responsible for the images they create (Rhodes 2009, Rhodes & Brown 2005, Van 
Maanen 1988). Constructing meaning also involves writing about the contexts, 
experiences, emotions, disciplinary constraints and power structures that shape 
the writing process (Denzin 2002, Rhodes 2009), which I have attempted to reveal 
in this introductory essay by writing about the research process and the meaning-
ful incidents that occurred in that process.
4.2 DATA COLLECTION
The first, third and fourth articles in my dissertation are based on empirical mate-
rial that I collected from several sources. In these articles, I use the data in different 
combinations that I explain in detail below. The second article in my dissertation 
is based on previous research and case studies, and I thus did not use any empiri-
cal data in that piece. 
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Table 1 presents an overview of my data. Because research should never be 
harmful to its participants (Ellis 2007, Eriksson & Kovalainen 2008), I have opted 
to remove all information that might compromise the anonymity of the partici-
pants from the articles and this introductory essay. Therefore, I have changed all 
company names and have not described the country or university in which the 
ethnographic data were collected. 
I began the data collection process by conducting telephone interviews. I chose 
five young companies from the Finnish biotechnology industry association’s mem-
ber list. These were all small or micro (Commission recommendation 2003/361/EC) 
companies with fewer than 50 employees. I chose young companies because I ex-
pected them to be at the point in their life cycle during which they must actively 
consider marketing activities but have not yet committed to any certain type of 
marketing. The interviews followed the model of narrative and open interviews; 
thus, the interviewees were encouraged to speak freely and with as little guidance 
from the interviewer as possible (Eriksson & Kovalainen 2008). I telephoned the 
companies and asked scientists to recount a story regarding how marketing had 
evolved in their company. I asked additional questions to clarify certain aspects of 
their stories. During the interviews, I did not propose any definitions of marketing 
because my aim was to determine what ‘marketing’ meant to the interviewees. 
The interviews were recorded and transcribed. I asked for permission to record at 
the beginning of the interview, and all the respondents agreed. Interviews were 
conducted in Finnish or English based on the respondent’s first language.
Table 1: Empirical data
Data Description Used in articles:
Article 
1
Article 
3
Article
4
Interviews (2007) Narrative and open interviews 
of the scientist-managers of five 
small Finnish biotechnology com-
panies in the fields of microbiol-
ogy, drug discovery, production 
of genetic tools and analysis.
x x
Documents (2007-2008) Web pages and media articles 
featuring the five companies that 
were interviewed.
x x
Ethnographic data 
2009-2011
An intensive, 24-month ethno-
graphic data collection process in 
which I acted as member of the 
university spin-off founding team 
under study. In total, these data 
include approximately 400 pages 
of notes, transcripts and docu-
ments.
x x
Focus group (2010) Group discussion with a univer-
sity technology transfer officer, a 
manager of a small biotechnolo-
gy company and a biotechnology 
business consultant.
x
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After the interviews were transcribed, I began to analyse them but soon realised 
that I required a more complete picture of the companies. In addition to the in-
terviews, I searched for media articles about the selected companies. I conducted 
searches using the company names and the names of the interviewees. I also 
studied the web pages of the companies involved in the study and press releases 
about their operations. All of the selected companies had web pages from which 
I was able to download press releases and white papers.
The ethnographic data were collected from a team of researchers aspiring to 
establish a university spin-off in the field of drug discovery. Before I became in-
volved, the entrepreneurial team consisted of the professor, members of his re-
search group at the pharmaceutical chemistry department, and a university tech-
nology transfer officer. I was initially asked to assist in writing the business plan. 
I began the project as more of an outside observer or mentor, but over time I as-
sumed a more active role in negotiating the shared understanding of the business 
opportunity. After the business plan that we had written together won a regional 
venture cup competition, they asked me to become a member of the founding 
team. I agreed, and we began to work toward securing funding and starting the 
business. At that stage, the team and I interacted with several interest groups, such 
as technology transfer officers at my university and various government agencies. 
The ethnographic data were collected from interactions that occurred within the 
entrepreneurial team and with third parties. My field notes are transcriptions of 
informal discussions. Telephone discussions were transcribed as accurately as 
possible after every call, as were the contents of personal, one-on-one discussions 
after every encounter. Skype chats and e-mails were saved as text files. In total, 
the data consist of approximately 400 pages of notes, transcripts and documents.
While collecting the ethnographic data, I wanted to assess how my interpreta-
tion of the biotechnology marketing and business resonated with different interest 
groups. Thus, I arranged a focus group discussion with a university technology 
transfer officer, a manager of a small biotechnology company and a biotechnology 
business consultant. This discussion was held in a restaurant over dinner in casual 
atmosphere and was recorded and transcribed.
Below, I will explain how I used and analysed the data in the articles.
4.3 METHODOLOGICAL CHOICES IN THE ARTICLES
Essay 1: The bridge: Connecting science and business
In this article, I focused on practices that were used to achieve a shared under-
standing of how science and business are combined in a biotechnology company. 
The article is based on the ethnographic data.
In this article, I used my ethnographic data and employed Georg Simmel’s 
(1997) concepts of the bridge and the door as the theoretical framework to analyse 
the connections between science and business. The concept of the bridge (Simmel 
1997) emphasises the practical task of connecting objects, phenomena or ideas 
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(Kaern 1994). In Simmel’s cultural theory, there are three distinct entities: form, 
content and individuals. When humans must perform a practical task, the interac-
tions then shape the content into forms, such as practices, which in turn constitute 
social reality. As in practice philosophy, Simmel (1997) regards the world as inher-
ently entangled: “We [human beings] are at any moment those who separate the 
connected or connect the separate”.
I began this analysis by reading the notes line-by-line and coding the elements 
related to separation and connection. Although I was interested in connections, I 
also coded the elements related to separation because, as Simmel (1997, 174) argues: 
“The human being is the connecting creature and cannot connect without separat-
ing – that is why we must first conceive intellectually of the merely indifferent exist-
ence of two river banks as something separated in order to connect them by means 
of a bridge.” This coding generated a list of themes, issues, categories, activities and 
patterns related to connection and separation. During the initial stage, I performed 
the coding with one of the researchers to incorporate his/her view into the analysis. 
In the next stage, I began organising the codes into categories. The codes that 
were similar in some respect or “felt alike” (Saldaña 2009) were grouped together 
to form a category. I grouped and regrouped the codes several times until I began 
to compare the categories using the concepts of the bridge and the door. The data 
contained there were several indications of socially constructed boundaries that 
defined certain individuals as insiders or outsiders; these boundaries included, for 
example, institutional, disciplinary and national boundaries. Only one category 
related metaphorically to the notion of a bridge: “the business plan”. It connected 
naturally separate objects and had a distinctive form and an individual existence 
with an aesthetic value and a history that developed over time. Thus, I placed that 
category under closer examination.
From the data coded in the bridge category, I created a narrative that incorporates 
ethno-dramatic vignettes into my autobiographical experience of those 24 months. 
Ethno-drama is the union of performance and ethnography, a genre of performance 
used for the interpretation and transfer of research (Alexander 2005, Rossiter et 
al. 2008). The concept is to transform ethnographically derived notes into theatri-
cal scripts or performance pieces that are highly evocative (Smith & Sparkes 2009, 
Mienczakowski 2001). The intent of an ethno-drama is to allow both the participants 
and the audience an opportunity to develop an aesthetic understanding of the lived 
experience through a staged re-enactment (Alexander 2005, Mienczakowski 2001). 
Essay 2: Anticipating and managing the challenges of biotechnology 
marketing
This essay is conceptual and does not employ empirical material. The material for 
the essay consists of the patents and case studies presented in the previous litera-
ture on the biotechnology industry. Because the research on small biotechnology 
companies was limited when the article was written, this essay also addresses 
cases concerning larger pharmaceutical companies. Although the focus of my 
36 37
dissertation is small biotechnology companies, I believe that it was appropriate to 
also discuss issues regarding larger companies because both types of companies 
face identical technological challenges, operate in identical markets and frequent-
ly form alliances with one another. In this article, I employ the framework for 
marketing in technology-intensive industries developed by Moriarty and Kosnik 
(1989) as a starting point; I discuss this framework and relate it to the case studies 
and the previous literature on the biotechnology industry to examine how the 
distinct features of biotechnology affect the applicability of this generalised model 
to the biotechnology industry.
Essay 3: Biotechnology marketing: Insider and outsider views
In this article, written with Päivi Eriksson, we used the telephone interviews and 
documentary data collected from the companies selected for interviews, and we 
focused on the marketing activities performed by these young biotechnology com-
panies. The analysis is based on the novel concept that combining the practition-
ers’ view (the emic perspective) with those of outsiders or researchers (the etic 
perspective) provides a fruitful starting point for a study on the topic (Agar 2007, 
Douglas & Craig 2006). This combination of outsider and insider perspectives not 
only considers meanings in the socio-cultural context of the biotechnology busi-
ness but also considers the practitioners’ vantage points relative to theoretical 
knowledge more broadly.
We began the analysis from the insider’s perspective. When studying biotech-
nology marketing from an insider’s perspective, the research interest lies in the fol-
lowing question: how do actors in the biotechnology sector explain what market-
ing means for biotechnology companies? We first wrote case descriptions for each 
company, using the definitions of marketing that the scientist-managers provided 
in the interviews as the central theme for each case. The scientist-managers cited 
certain traditional marketing activities such as advertising, brand-building and 
mailing campaigns. In addition, they described activities that are highly context 
specific and not typically described in traditional marketing textbooks, including 
presenting at scientific conferences and publishing articles in academic journals. 
After addressing the insider’s perspective, we analysed the case descriptions 
further by adding the outsider’s perspective. The aim of this approach is to un-
derstand the world of marketing in scientific terms and assumes that theory and 
constructs are universal and applicable across countries, industries and compa-
nies. When studying biotechnology marketing from an outsider’s perspective, 
the research interest lies in the following question: how do researchers as outside 
observers explain what marketing is in biotechnology companies? Therefore, we 
began to analyse both the interview and documentary data and identified market-
ing activities that were not necessarily cited by the interviewees. 
Finally, we performed a cross-case analysis that focused on the differences and 
similarities among the cases. 
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Essay 4: The science marketing practice of a biotechnology start up 
In this unpublished manuscript, written with Päivi Eriksson, we consider all the 
empirical data I collected for my dissertation. However, the primary data source 
remains the ethnographic data. 
In our previous study (Eriksson & Rajamäki 2010) we found a variety of activi-
ties that we divided into two categories. The first, ‘generic marketing’, included 
activities typically described in the marketing literature and included sales, adver-
tising and brand building. The second, ‘science marketing’, consisted of activities 
that were originally strictly science-related activities but have been adopted by 
companies as part of their marketing activities (Eriksson & Rajamäki 2010). In our 
analysis, we utilised the concepts of generic marketing and science marketing as 
sensitising concepts.
We began the analysis by reading the data carefully and attempting to identify 
activities that were related to both generic and science marketing. Whereas our 
interest in the previous article was marketing activities, in this article, we commit 
to the strong practice-based programme by using the practice theoretical frame-
work (Nicolini 2013, Gherardi 2012, Reckwitz 2002). Accordingly, we began with 
marketing actions to recognise the related agents, objects, knowledge and routines 
that form the basic elements of practice (Reckwitz 2002). These activities included 
sales, advertising, writing articles and speaking at conferences. Practice theory 
stipulates that practice is a constellation of smaller elements that are enacted in 
action (Nicolini 2013, Reckwitz 2002). Therefore, we began to search for the vari-
ous elements of practice that were part of the identified activities. We noticed, for 
example, that when giving lectures, the body travelled to the conference location 
and objects such as PowerPoint slides were used in that action. Thus, we were able 
to map out constellations of actions, bodies, minds, individual agents, communi-
ties, knowledge and objects to grasp the practices that hold those constellations 
together. At that point, we had not yet drawn a distinction between routine and 
non-routine activities; as in the transfer of practice, activities are only routinised 
during the final stage when the practice is institutionalised (Gherardi & Perrotta 
2010, Szulanski 1996). During the final stage of the analysis, we focused on wheth-
er and how routinisation occurred when the constellations evolved over time. 
Working in this manner, we sorted and organised our data and developed a 
story to describe the practice of biotechnology marketing. The story is written in 
the form of ethnographic fiction (Richardson & St.Pierre 2008, Rhodes & Brown 
2005) on the subject of Professor Jackson and his team. All characters in the story 
are composites (Ellis 2004) such that Professor Jackson is an imaginary character 
in whom we included the characteristics, opinions and quotes of several different 
professors found in our data. Composite characters are a useful way of presenting 
key ideas in the data more concisely than introducing all informants as different 
characters in the story (Ellis 2004). Importantly, using composite characters also 
provides a means to protect the real identities of the informants (Richardson & 
St.Pierre 2008, Rhodes & Brown 2005). To ensure the credibility of the story, we 
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allowed two biotechnology practitioners to read and comment on it (Van Maanen 
1988, Riessmann 1993, Fini et al. 2009). Based on the comments of these reviewers, 
we made a few minor revisions to render the story more plausible.
After the story, we present our analysis of the agents, objects, knowledge and 
routines and how these elements are interlinked and organised. During the anal-
ysis, we identified activities first because actions are always part of a practice 
(Corradi et al. 2010, Reckwitz 2002). Thereafter, we began to identify the different 
elements of practice described by Reckwitz (2002) and were able to map out con-
stellations of actions, bodies, minds, individual agents, knowledge and objects.
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5 Results
“How we are expected to write affects what we can write about” (Richardson 2000, 7).
I was ecstatic when one of my articles passed the first review at a journal that I re-
spected highly. In all honesty, passing this review was beyond my greatest expectations. 
The unfortunate news was that the reviewers insisted on major revisions. For example, 
one of them required me to conduct the literature review again and position my study in an 
entirely different field. My fellow doctoral students were horrified when I told them about 
this development: “Oh no, how are you going to reply to that?” In reality, I had only one 
choice: “I am going to do exactly what they are asking me to do”.
The reason I inserted these brief excerpts that describe the making of my dissertation 
is to acknowledge that “…knowledge and its writing are actively produced by particular 
decisions and actions taken” (Rhodes 2009, 666). Therefore, in an attempt to make my rep-
resentations more honest and truthful, I have written straightforwardly about the context 
of this study: my personal background, experiences, emotions, conflicting world views, 
academic conventions and the institutional power structures I confronted to demonstrate 
how they have shaped my scholarship (Denzin 1997, Motzafi-Haller 1997) and the render-
ing of reality in my scholarship (Denzin 2002, Rhodes 2009). These considerations shaped 
the entire process of developing my study: how I embarked on this journey, how I collected 
my empirical material and how and what I have written about it. As Laurel Richardson 
(2001, 879) has written: “Writing is never innocent”. I think a sterile, neatly organised and 
polished text is rather suspicious (Pullen & Rhodes 2008).
My dissertation consists of three published articles and one unpublished manu-
script. I described above the theoretical underpinnings of these articles and the 
empirical data analysis. Below, I will briefly introduce the studies to discuss their 
findings and how they contribute to my main research question.
5.1 THE BRIDGE: CONNECTING SCIENCE AND BUSINESS
Rajamaki, H. Culture and Organization Vol. 17, No. 3, June 2011, 
199–212
In this article, I explore the practices that create the shared conception of a busi-
ness opportunity. This article focuses on the feature that is uniquely distinctive 
of the biotechnology business: working at the intersection of scientific knowledge 
production and commercial gain. The literature has treated boundary spanning 
as unproblematic, when, in fact, it requires competence; otherwise, agents would 
simply reproduce boundaries instead of translating knowledge across boundaries 
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(Levina & Vaast 2005). This article attempts to fill this gap by exploring how it is 
possible to connect science and business, i.e., how certain groups of individuals 
are able to jointly connect and create new ventures. To study this combination of 
science and business, I use Simmel’s (1997) concept of the bridge, as expressed in 
his essay ‘Bridge and Door’, as the theoretical framework that hones the focus of 
my investigation. The bridge emphasises the practical task of connecting objects, 
phenomena and/or ideas (Kaern1994) that are naturally separated but that can be 
connected by an act of human will. 
During the fieldwork for this study, I became increasingly uncomfortable read-
ing research from the perspective of an outsider (Eriksson and Rajamäki 2010) on 
an institutional level (Djockovic & Souitaris 2008) who is reporting on the con-
flicts, problems and incompetence of scientist-entrepreneurs. After examining the 
phenomena as an insider, I realised, as Shane & Khurana (2003) have underscored, 
that this type of research is a ‘little bit like a murder mystery in which the victim 
is killed for no reason at all. That is to say, one doesn’t get any sense of the reasons 
or individual motives that account for the existence of a particular organisation 
and the characteristics it has’ (Olson 1986, 178– 179). I recognised that there was a 
need for research that would generate an empathetic understanding of the busi-
ness of biotechnology and its marketing and that would thereby provide a sense of 
why individuals do certain things—what their motives are and, more importantly, 
what the nature of their experiences is.
Based on the ethnographic data, I created a layered narrative (Denzin 2002, 
Rambo 2007) to illustrate how the bridge was built and how it facilitated shared 
interpretations. I chose to use performance-based writing because it has the po-
tential to create change by helping the audience, participants, and researchers 
to think critically about their worlds (Alexander 2005). A well-written, perfor-
mance-based narrative affects the audience emotionally and evokes empathy and 
a new understanding of characters’ lives; it persuades the audience to think criti-
cally about the social and personal realities involved in the situation represented 
(Morgan et al. 2001).
In the study, I described how the genesis of the spin-off was not a quest for 
profit. Instead, its origins began as a response to the threat of unemployment be-
cause of diminishing or discontinued funding for the group. The company had 
to secure employment for its members and allow them to continue their scientific 
work. Therefore, it is understandable that the researchers did not have any specific 
aspirations to become entrepreneurs; these researchers still wished to be scientists 
first and foremost. A business scholar might wonder whether the company that 
these scientists sought to establish would truly be a for-profit business or whether 
it would instead become a non-profit organisation. I believe that these were the 
first signs that the business of biotechnology, and therefore biotechnology market-
ing, is based on a different logic than that described in the traditional business 
and marketing literature. 
The business plan was created as a bridge between science and business, which 
helped connect two different social worlds and created a shared understanding 
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between these worlds. The “bridge building” was not without conflict; in the ar-
ticle, I illustrate how the business consultants and I were able to act as mediators 
to help individuals from different contexts to (first) communicate and (second) 
create a shared understanding. Thus, the shared understanding of the marketing 
philosophy and strategy was created in writing the business plan. 
Simmel (1997) noted that crystallised forms occasionally become detached 
from their original purpose and that cultivating those forms can become an end 
in itself. This phenomenon occurred in our case; writing and re-writing the plan 
nearly became the sole purpose for interaction among the different interest groups. 
5.2 ANTICIPATING AND MANAGING THE CHALLENGES OF 
BIOTECHNOLOGY MARKETING
Rajamäki, H. Journal of Commercial Biotechnology (2008) 14, 225 – 231
This article is a theoretical review of the literature on the biotechnology busi-
ness, the diffusion of technology and the marketing efforts of technology-intensive 
companies. When this article was published, there were no articles that presented 
frameworks or conceptualisations of the specific characteristics of the biotechnol-
ogy industry and how these characteristics might affect marketing. In addition, 
the previous biotechnology business literature primarily addressed large biotech-
nology or pharmaceutical companies. Nonetheless, these large companies operate 
in the same markets as smaller biotechnology companies.
The article addresses the practice-theory gap by examining features that are 
distinctively important in biotechnology marketing. I discuss the features that dis-
tinguish biotechnology marketing from that found in more established industries 
and the key challenges for biotechnology marketing arising from those differences.
The biotechnology industry and high technology industries in general are 
characterised by involving emergent technologies. Therefore, and because of the 
lack of any biotechnology-specific framework, I apply the concepts that Moriarty 
& Kosnik (1989) develop about the particular characteristics of high-technology 
industries and the framework of high-technology marketing as a starting point. 
Moriarty & Kosnik (1989) present this framework to explain why high-technology 
marketing differs from marketing for a traditional product or service and con-
tend that there are two dimensions that distinguish high-technology from low-
technology marketing situations. First, there is market uncertainty, which refers 
to the uncertainty regarding the extent and type of customer needs that a given 
technology can satisfy. Market uncertainty originates from the market: its struc-
ture, changes and dynamics. Second, there is technological uncertainty regarding 
the technology’s ability to satisfy customer needs. This type of uncertainty has a 
purely technological origin. 
In the article, I take market and technological uncertainty as starting points 
and, using previous studies of the biotechnology industry, discuss how some of 
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the features that are typical of technology-intensive companies are not typical of 
biotechnology companies. Based on this discussion, I present six key challenges 
that biotechnology marketers face. These challenges are the unique decision areas 
for biotechnology. First, profound technological uncertainty is a key characteris-
tic of biotechnology. Second, side effects emerging after the product has been in 
the market can cause the discontinuation of entire product lines or reduced esti-
mated market potential. Third, a biotechnology product’s lifecycle can also face 
premature death because of challenges originating from market uncertainties. A 
fourth issue is the threat of obsolescence, which is high in a market in which new 
innovations are introduced at a rapid rate. The fifth issue is the ability to protect 
intellectual property rights. Ultimately, these challenges make it difficult to esti-
mate the size of a potential market. 
As previous research has indicated, instead of being pre-defined structures, 
markets are constructed and shaped by multiple practices performed by differ-
ent actors, including companies and customers (Slater 2002, Araujo et al. 2008, 
Kjellberg & Helgesson 2006). These actors always undertake their actions within 
a constantly evolving historical-cultural setting (Corradi et al. 2010) that takes 
highly distinctive forms, each with its own challenges (Peñaloza & Venkatesh 
2006). The biotechnology industry has emerged in a novel setting compared to 
more traditional industries (Pisano 2010). The six challenge areas that I present 
in the article reveal how its basis in science makes biotechnology markets and 
businesses special in a way that makes general marketing concepts inapplicable. 
5.3 BIOTECHNOLOGY MARKETING: INSIDER AND OUT-
SIDER VIEWS
Eriksson, P. & Rajamäki, H. Journal of Commercial Biotechnology 
(2010) 16, 98–108
In this article, we employ the concepts of science marketing and generic market-
ing. 
This article, written with Päivi Eriksson, explores the activities of biotechnol-
ogy marketers. We address this issue by focusing on marketing as defined, per-
formed and organised in small biotechnology companies. 
Prior research has argued that, on the one hand, marketing-related deficien-
cies might explain the lack of commercial success in biotechnology. On the other 
hand, it has been suggested that biotechnology marketing might differ from what 
is considered marketing in other industries and has thus remained unexplored 
by the survey-based research designs used in prior studies. Our article builds on 
this interesting contradiction in the literature.  
The previous literature has demonstrated little interest in how biotechnology 
companies operate and the types of managerial activities they perform. Although 
the definitions managers gave of their marketing activities were not extensive, 
44 45
we were able to identify a rich variety of marketing activities that these small 
companies perform. Combining insider and outsider perspectives, we identified 
two types of marketing: generic and science marketing. We use the term “generic 
marketing” to refer to the type of marketing found in textbooks and the main-
stream marketing literature, including the sales, advertising, business-to-business 
communication, sponsoring and brand building literatures. 
Biotechnology companies also engage in science-related activities that are typi-
cal found in the academic world that target scientists working in academia and 
in private industry. The key activities of science marketing include publishing in 
academic journals, presenting at scientific and professional conferences, compil-
ing reference lists, being cited, and providing information on all these activities 
on company web pages and printed brochures.  
On the basis of our findings, we argue that science marketing is a relevant 
aspect of biotechnology marketing and should be studied in greater detail. This 
finding does not suggest that there is a substantial lack of marketing effort and 
competence in biotechnology companies. Instead, the findings offer new insights 
about the specific nature of biotechnology marketing that is produced by a com-
bination of insider and outsider views. 
5.4 THE SCIENCE MARKETING PRACTICE OF A BIOTECH-
NOLOGY START UP  
Rajamäki H. & Eriksson, P., unpublished manuscript
In this article, we argue that a practice-based approach is necessary to comprehen-
sively understand biotechnology companies’ marketing efforts. The gap between 
marketing theory and practice is a recurring theme, particularly in the context of 
small businesses (Reijonen 2010, Coviello et al. 2000) and/or new ventures (Stasch 
1999). In contrast with theory, the marketing planning process employed by small 
companies is less formal (Gilmore et al. 2001, Coviello et al. 2000) and includes 
different types of techniques (Zontanos & Anderson 2004, Stasch 1999, Eriksson 
& Rajamäki 2010). Small companies do not have specific marketing departments 
or personnel dedicated to marketing (Hagberg & Kjellberg 2010, Simpson et al. 
2006); instead, their marketing tasks are the responsibility of generalists or part-
time marketers (Gilmore et al. 2001, Hogarth-Scott et al. 1996). Therefore, we re-
quire a more contextualised understanding of marketing. As a reaction to the 
practice-theory debate, the marketing-as-practice approach attempts to account 
for how marketing is actually performed in organisations (Araujo 2007, Kjellberg 
& Helgesson 2007, Schau et al. 2009).
 In this article, we use the practice theoretical framework (Nicolini 2013, 
Gherardi 2012, Reckwitz 2002) to analyse marketing practices in biotechnology 
companies. With a particular emphasis on activities related to bodies, we demon-
strate that science work and science marketing are different practices in nature. 
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Furthermore, we reveal that biotechnology marketing and sales are built on a 
foundation of “science marketing” that was originally constructed to promote 
the academic expertise of scholars or research groups. Scientific work is marketed 
to other academics to promote citations and to funding organisations to support 
grant applications. Research groups also actively sell their services to companies 
by conducting collaborative projects, which makes it possible for research groups 
to fund their operations and laboratories.
Once a company is founded, the practice is fine-tuned to fit the business en-
vironment. In addition, elements that are considered relevant may be added to 
the practice. One example is a website originally developed for a research group 
that is then made more business-like. Another example involves academic confer-
ence presentations that include a company advertisement as the final presentation 
slide. Our analysis indicates that science marketing practice, as introduced in this 
article, is based on well-known routines utilised to promote research results and 
the academic expertise of scientists and their research groups. Once scientists 
establish a biotechnology company, their embodied competence and well-refined 
routines are transferred and fine-tuned to fit their businesses. Based on these find-
ings, we suggest that what such science-based, biotechnology start-up companies 
understand as marketing differs considerably from the meaning of the term in 
other small companies that do not have a strong science background.
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6 Conclusion
Returning to the beginning of my story, sitting in my car in a university parking lot in the 
middle of night, I believed that I could see what was inside, in a metaphorical sense. I was 
thrilled to find marketing activities in the place I least expected them. It came in the form 
of science marketing, a carefully thought-out and planned set of activities performed to 
promote the research group. Spending time “inside”, I learned to appreciate the particular 
features of the context in which biotechnology companies are created, and it began to make 
sense to me that combining science marketing with more traditional techniques was a 
natural response in this context. I believe that adopting an open-minded perspective about 
practitioners’ actual activities—rather than focusing on how things “should” be done—of-
fers an opportunity to learn something new and even unexpected. 
6.1 FINDINGS 
At the nexus of science and business, the essence of biotechnology has certain 
unique characteristics that distinguish it from other industries. Acknowledging 
this background is of paramount importance because the particular character-
istics of the industry and its evolution affect marketing decision areas and the 
activities performed by marketing practitioners. Although the knowledge of this 
specific type of marketing may seem narrow and local, it involves marketing work 
and may affect the survival of over 2000 biotechnology companies that employ 
100,000 individuals in Europe alone.  
An approach that appreciates the practitioners’ view accounts for the particu-
lar characteristics of the industry and thus is capable of acquiring a more contextu-
alised picture of marketing in the biotechnology industry. This study has revealed 
a new type of marketing that is distinctively different from that presented in the 
literature. Identifying new types of marketing has great significance for marketing 
theory in general. As Geertz (2000, 138) has written: “Theory…grows out of par-
ticular circumstances”. Comparing marketing practices in different and specific 
contexts, such as biotechnology, allows us to recognise the diversity and richness 
of marketing practices and thus broadens the concept of marketing in general. 
The results of this study suggest that insights generated from this line of inquiry 
have the potential to broaden marketing concepts in this context and thus provide 
relevant and valuable insights for both marketing practice and academic research 
(Srinivasan 2008, Stemersch & Van Dyck 2009).
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6.2 THEORETICAL AND METHODOLOGICAL 
CONTRIBUTION 
This study contributes to the areas of biotechnology marketing and the more gen-
eral discussion of the concepts of marketing and small business marketing by 
offering a novel perspective on marketing in small biotechnology companies. By 
accounting for the contextual nature of the marketing concept and appreciating 
the practitioners’ perspective, this study reveals a new type of marketing, science 
marketing, which has not yet been identified by the methodologies utilised in the 
extant literature.
The concept of science marketing permits a new interpretation of issues pre-
sented in the previous literature. For example, the application of the traditional 
process model of marketing to certain contexts has resulted in perceptions of 
incompetence in marketing (see, e.g., Costa et al. 2004). The practice framework 
questions such conclusions. The marketing process is essentially different in bio-
technology companies, and practices in this industry are built on solid existing 
skills. By adopting this new approach, the entire phenomenon of biotechnology 
marketing is more understandable. Other examples include science marketing ac-
tivities that are specific to a field, such as publishing articles or giving conference 
presentations, which the literature has regarded as a myopic preoccupation with 
technology (Levitt 1975); however, the practice approach reveals these functions 
to be understandable aspects of marketing practice.  
The results of this study indicate that biotechnology marketing is based on 
routines that were originally developed to promote the academic expertise of 
scholars and/or research groups. Once the company is established, these prac-
tices are then fine-tuned to fit the business environment. In addition, elements 
and routines from more general marketing practices that are considered relevant 
are added. As a result, a biotechnology marketing practice consists of intertwined 
elements of scientific work and generic marketing, which distinguishes it from the 
traditional marketing concepts and processes presented in the literature. 
This study also contributes to the growing body of marketing-as-practice re-
search and demonstrates how the framework can be applied to generate new un-
derstanding. Thus, this study reveals a new approach to examining and acquiring 
new types of knowledge about marketing in specific contexts. This study dem-
onstrates how the practice-oriented approach has the potential to provide new 
insights about what is considered relevant by practitioners. 
By adopting the practice approach, this study shows that it is possible to broad-
en and understand biotechnology marketing more comprehensively. The insider 
view allows scholars to understand biotechnology practitioners’ activities: what 
their motives are and, more importantly, what their experiences are. However, the 
researcher’s view is equally important; for example, taken-for-granted assump-
tions must be studied by an outsider because unconscious assumptions may not 
be visible to the practitioners themselves.
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6.3 PRACTICAL IMPLICATIONS
The message for managers of biotechnology companies is that it is both relevant 
and legitimate to acknowledge the role of science marketing in the operations of 
biotechnology companies; it is also relevant to consider how science marketing 
can be combined with generic marketing in a fruitful way. 
Acknowledging the existence of the two forms of marketing should also be 
useful when considering how marketing can be organised and how marketing 
competences can be further developed. This study suggests that studying the re-
lationship between, and the dynamics of, these two types of marketing in greater 
detail would generate improved knowledge about biotechnology marketing both 
for researchers and practitioners.
6.4 LIMITATIONS AND FURTHER RESEARCH
The results of this study present interesting avenues for further study. This study 
identified a new type of marketing, science marketing, that is essentially differ-
ent from traditional concepts of marketing. A more detailed study of the concept 
of science marketing might yield valuable insights on how the historical, cultural 
and institutional context affects the multiplicity of shapes that marketing can take 
in specific situations. 
The ethnographic data in this study were collected from a single company 
in its early stages of operation. They provide a valuable picture of the bases of 
marketing practice, i.e., scientific work and traditional marketing, and how these 
aspects can begin to intertwine during the early years of business operations. 
Moreover, the interview data in this study were collected from small and young 
biotechnology companies. Continuing to follow these companies and adding data 
from more established biotechnology companies might produce insights on how 
marketing practice continues to evolve as companies grow.
Using the practice approach, this study depicts marketing in a way that makes 
certain activities such as publishing articles an understandable and logical com-
ponent of marketing practice. However, because of this study’s scope, the concept 
of science marketing continues to be presented at a general level. A more fine-
grained analysis of the various aspects of practice might provide a more compre-
hensive view of the concept. First, an interesting avenue for closer study would be 
the patterns of the doings, sayings and interactions among various interest groups 
such as scientists, technology transfer officers and financiers. Small biotechnol-
ogy companies operate at the intersection of different cultural and institutional 
boundaries. Therefore, the second interesting area for future research concerns 
these very tensions, rules and power structures that shape science marketing prac-
tice. Third, focusing on the artefacts and how they are used by and simultane-
ously shape science marketing practice might provide interesting insights into the 
largely ignored research area of artefacts in everyday marketing work. I suggest 
that these avenues of research might broaden the concept of marketing and rec-
ognise the myriad shapes of marketing practice.
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